Clinical Observation of Glycyrrhiza Polysaccharide Capsules Combined with Budesonide and Formoterol Powder Inhaler in the Treatment of COPD

目的：评价甘草多糖胶囊联合布地奈德福莫特罗粉吸入剂治疗慢性阻塞性肺疾病稳定期患者的有效性及安全性。方法：选取2021年12月至2022年12月就诊于甘肃省中医院且符合COPD稳定期患者88例，采用随机数字表法分为对照组和治疗组，每组44例。对照组予布地奈德福莫特罗粉吸入剂加安慰剂胶囊，治疗组予布地奈德福莫特罗粉吸入剂加甘草多糖胶囊，2个月后测定患者的T淋巴细胞亚群水平、肺功能、CAT评分、mMRC，评价甘草多糖治疗COPD的疗效。结果：经统计分析结果显示，对照组与治疗组临床均有效，治疗组疗效明显优于对照组，能够有效缓解临床症状。经治疗，治疗组患者T淋巴细胞亚群(CD3+, CD4+, CD4+/CD8+)、肺功能(FEV1, FVC, FEV1/FVC)、CAT评分、mMRC评分均明显改善(P P > 0.05)。结论：甘草多糖胶囊联合布地奈德福莫特罗粉吸入剂能够显著改善患者肺功能，提高机体免疫力，而对肝、肾功能几乎无不良影响，具有临床推广价值。Objective: To evaluate the efficacy and safety of Glycyrrhiza Polysaccharide Capsules combined with Budesonide and Formoterol Powder Inhaler in the treatment of patients with stable chronic obstructive pulmonary disease (COPD). Methods: Eighty-eight COPD patients in the stable phase, admitted to Gansu Provincial Hospital of Traditional Chinese Medicine from December 2021 to December 2022, were selected and randomly divided into a control group and a treatment group (44 cases each) using the random number table method. The control group received Budesonide and Formoterol Powder Inhaler plus placebo capsules, while the treatment group received Budesonide and Formoterol Powder Inhaler plus Glycyrrhiza Polysaccharide Capsules. After two months, T lymphocyte subset levels (CD3+, CD4+, CD4+/CD8+), pulmonary function (FEV1, FVC, FEV1/FVC), COPD Assessment Test (CAT) score, and modified Medical Research Council (mMRC) dyspnea scale were measured to evaluate therapeutic outcomes. Results: Statistical analysis revealed clinical efficacy in both groups, with significantly superior outcomes in the treatment group. Post-treatment, the treatment group exhibited marked improvements in T lymphocyte subsets (CD3+, CD4+, CD4+/CD8+), pulmonary function parameters (FEV1, FVC, FEV1/FVC), CAT score, and mMRC score (P P > 0.05). Conclusion: Glycyrrhiza Polysaccharide Capsules combined with Budesonide and Formoterol Powder Inhaler significantly enhance pulmonary function and immune response in stable COPD patients without adverse effects on liver or kidney function, demonstrating substantial clinical value for broader application.